Evogene (EVGN) Other Non Operating Income (2020 - 2021)
Evogene (EVGN) posted Other Non Operating Income of $551000.0 for Q2 2021, up 34.72% sequentially from $409000.0 in Q2 2020, and up 34.72% YoY from $409000.0 in Q2 2020.
Evogene (EVGN) Other Non Operating Income (2020 - 2021) Analysis & Trends
Evogene has reported Other Non Operating Income for 2 years, with the latest figure at $551000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 551,000.00 |
| Jun 30, 2020 | 409,000.00 |